ProCE Banner Activity

How to Treat Relapsed/Refractory Multiple Myeloma in 2020

Slideset Download
Download this slideset from Jesús F. San-Miguel, MD, PhD to review data on available treatment options for patients with relapsed/refractory myeloma.

Released: December 04, 2020

Expiration: December 03, 2021

Share

Faculty

Brian G. M. Durie

Brian G. M. Durie, MD

National Director, Hematologic Malignancies and Multiple Myeloma
Aptium Oncology, Inc.
Co-Chair, Myeloma Committee – SWOG
Chairman, International Myeloma Foundation
Specialist, Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California

Jesús F. San-Miguel

Jesús F. San-Miguel, MD, PhD

Head, Hematology Department
Professor of Medicine
Hospital Universitario de Salamanca and Centro de Investigación del Cáncer
University of Salamanca
Salamanca, Spain

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Bristol Myers Squibb

GlaxoSmithKline

Karyopharm

Oncopeptides

Partners

International Myeloma Foundation

ProCE Banner

Faculty Disclosure

Primary Author

Brian G. M. Durie, MD

National Director, Hematologic Malignancies and Multiple Myeloma
Aptium Oncology, Inc.
Co-Chair, Myeloma Committee – SWOG
Chairman, International Myeloma Foundation
Specialist, Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California

Jesús F. San-Miguel, MD, PhD

Head, Hematology Department
Professor of Medicine
Hospital Universitario de Salamanca and Centro de Investigación del Cáncer
University of Salamanca
Salamanca, Spain